CA2867381C - Controlled release formulations for the delivery of hif-1 inhibitors - Google Patents
Controlled release formulations for the delivery of hif-1 inhibitors Download PDFInfo
- Publication number
- CA2867381C CA2867381C CA2867381A CA2867381A CA2867381C CA 2867381 C CA2867381 C CA 2867381C CA 2867381 A CA2867381 A CA 2867381A CA 2867381 A CA2867381 A CA 2867381A CA 2867381 C CA2867381 C CA 2867381C
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- hif
- polymeric conjugate
- dxr
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611931P | 2012-03-16 | 2012-03-16 | |
US61/611,931 | 2012-03-16 | ||
PCT/US2013/030533 WO2013138343A1 (en) | 2012-03-16 | 2013-03-12 | Controlled release formulations for the delivery of hif-1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2867381A1 CA2867381A1 (en) | 2013-09-19 |
CA2867381C true CA2867381C (en) | 2016-09-20 |
Family
ID=47913636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2867381A Active CA2867381C (en) | 2012-03-16 | 2013-03-12 | Controlled release formulations for the delivery of hif-1 inhibitors |
Country Status (9)
Country | Link |
---|---|
US (2) | US8962577B2 (zh) |
EP (1) | EP2825206A1 (zh) |
JP (1) | JP5883539B2 (zh) |
CN (1) | CN104363924B (zh) |
AU (1) | AU2013232297B2 (zh) |
CA (1) | CA2867381C (zh) |
EA (1) | EA032552B1 (zh) |
HK (1) | HK1206270A1 (zh) |
WO (1) | WO2013138343A1 (zh) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
CA2867381C (en) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
CN104394891B (zh) | 2012-03-16 | 2019-04-16 | 约翰霍普金斯大学 | 用于递送活性剂的非线性多嵌段共聚物-药物结合物 |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2871745C (en) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3041479B1 (en) | 2013-09-06 | 2023-04-26 | Vanda Pharmaceuticals Inc. | Treatment of cyr61- and vegf-mediated conditions |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
JP6407257B2 (ja) * | 2014-03-31 | 2018-10-17 | 千寿製薬株式会社 | アルキニルインダゾール誘導体及びその用途 |
US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
EP3227348A4 (en) | 2014-12-04 | 2018-07-18 | The Trustees of Columbia University in the City of New York | Biodegradable thermo-responsive polymers and uses thereof |
US10525034B2 (en) | 2014-12-15 | 2020-01-07 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
US20180008718A1 (en) * | 2015-01-20 | 2018-01-11 | The Johns Hopkins University | Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure |
US10485757B2 (en) | 2015-01-27 | 2019-11-26 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
US10695427B2 (en) * | 2015-04-06 | 2020-06-30 | The Johns Hopkins University | Shape memory particles for biomedical uses |
CA2995582A1 (en) * | 2015-08-19 | 2017-02-23 | Children's Research Institute, Children's National Medical Center | Compositions and methods for treating graft versus host disease |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
CN108366984A (zh) | 2015-09-22 | 2018-08-03 | 灰色视觉公司 | 用于治疗眼部病症的化合物和组合物 |
CN108367079B (zh) | 2015-11-12 | 2022-11-22 | 灰色视觉公司 | 用于治疗的聚集性微粒 |
PT3448421T (pt) * | 2016-04-29 | 2022-01-14 | Univ Leland Stanford Junior | Métodos e composições para a prevenção e tratamento de aderências cirúrgicas |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
CN110167958A (zh) * | 2016-07-26 | 2019-08-23 | 北卡罗来纳大学教堂山分校 | 载体介导的眼睛免疫耐受性 |
MX2019011242A (es) | 2017-03-23 | 2020-01-21 | Graybug Vision Inc | Farmacos y composiciones para el tratamiento de trastornos oculares. |
BR112019022908A2 (pt) | 2017-05-10 | 2020-05-26 | Graybug Vision, Inc. | Micropartícula de agregação sólida, sólido liofilizado ou reconstituível de micropartículas de agregação, método para tratamento de um distúrbio ocular, e, uso das micropartículas de agregação sólidas |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
CN113365617A (zh) | 2018-10-16 | 2021-09-07 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
WO2021168239A1 (en) * | 2020-02-21 | 2021-08-26 | The Johns Hopkins University | Suprachoroidal delivery of drug particles to reduce toxicity |
US20230241256A1 (en) * | 2020-06-30 | 2023-08-03 | The Johns Hopkins University | Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors |
CN115364199A (zh) * | 2021-05-19 | 2022-11-22 | 远大医药(中国)有限公司 | 包含pedf衍生的短肽的组合物及其制备方法和用途 |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
GB929406A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | A process for the production of encapsulated material |
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
GB969808A (en) | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
US4027676A (en) | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
US4201216A (en) | 1976-12-15 | 1980-05-06 | Ethicon, Inc. | Absorbable coating composition for sutures |
IT1148784B (it) | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
DE3264050D1 (en) | 1981-08-24 | 1985-07-11 | Unilever Nv | Lavatory cleansing block |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
GB2172594B (en) | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
US4857602A (en) | 1986-09-05 | 1989-08-15 | American Cyanamid Company | Bioabsorbable surgical suture coating |
US4789724A (en) | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US4994074A (en) | 1990-02-01 | 1991-02-19 | Ethicon, Inc. | Copolymers of ε-caprolactone, glycolide and glycolic acid for suture coatings |
US5196522A (en) | 1990-11-01 | 1993-03-23 | Board Of Regents, The University Of Texas System | Anthracycline analogues bearing latent alkylating substituents |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
AU673160B2 (en) | 1992-02-28 | 1996-10-31 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
EP0712421A1 (en) | 1993-07-23 | 1996-05-22 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5522842A (en) | 1994-03-11 | 1996-06-04 | Poly-Med, Inc. | Absorbable Ε-caprolactone polymers as suture coatings displaying auto catalyzed hydrolysis |
WO1995024412A1 (fr) | 1994-03-11 | 1995-09-14 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Nouveaux derives d'anthracycline contenant une unite de sucre trifluoromethyle |
IT1272234B (it) | 1994-05-02 | 1997-06-16 | Consiglio Nazionale Ricerche | Derivati glutationici delle antracicline e procedimento per ottenerli. |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
US5628981A (en) | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
ES2227536T3 (es) * | 1995-06-27 | 2005-04-01 | Pharmachemie B.V. | Nuevos profarmacos de antraciclina, procedimiento de preparacion asi como su uso en quimioterapia selectiva. |
US5869130A (en) | 1997-06-12 | 1999-02-09 | Mac Dermid, Incorporated | Process for improving the adhesion of polymeric materials to metal surfaces |
GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
DK1032605T3 (da) * | 1997-09-10 | 2008-03-17 | Univ Rutgers | Polyanhydrider med terapeutisk anvendelige nedbrydningsprodukter |
US6235869B1 (en) | 1998-10-20 | 2001-05-22 | United States Surgical Corporation | Absorbable polymers and surgical articles fabricated therefrom |
US20040258763A1 (en) | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
US20060194008A1 (en) | 1999-09-22 | 2006-08-31 | Princeton University | Devices with multiple surface functionality |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
WO2002013701A1 (en) | 2000-08-17 | 2002-02-21 | Tyco Healthcare Group Lp | Sutures and coatings made from therapeutic absorbable glass |
EP1353701B1 (en) | 2000-10-31 | 2011-12-21 | PR Pharmaceuticals, Inc. | Methods for producing compositions for enhanced delivery of bioactive molecules |
SI1381382T1 (sl) | 2000-11-01 | 2009-04-30 | Merck Patent Gmbh | Postopki in sestavki za zdravljenje oäśesnih bolezni |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US6932894B2 (en) | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
EP1411926B1 (en) | 2001-08-01 | 2005-06-01 | MERCK PATENT GmbH | Integrin inhibitors for the treatment of eye diseases |
GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
DE10146264A1 (de) | 2001-09-20 | 2003-04-17 | Ecolab Gmbh & Co Ohg | Verwendung von O/W-Emulsionen zur Kettenschmierung |
KR20050037992A (ko) | 2002-06-05 | 2005-04-25 | 유니버시티 오브 플로리다 | 안약 전달 장치 |
US7122189B2 (en) * | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
BR0316685A (pt) | 2002-12-17 | 2005-11-01 | Nastech Pharm Co | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade |
KR101045504B1 (ko) * | 2002-12-30 | 2011-06-30 | 넥타르 테라퓨틱스 | 약물 전달 부형제로서의 멀티-아암 폴리펩티드-폴리(에틸렌글리콜) 블록 공중합체 |
WO2004064860A1 (en) | 2003-01-17 | 2004-08-05 | Children's Hospital Medical Center | Use of tff2, or agents inducing tff2, in the therapy of allergies |
US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
GB0328630D0 (en) | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
US7329271B2 (en) | 2003-12-18 | 2008-02-12 | Ethicon, Inc. | High strength suture with absorbable core |
US7357810B2 (en) | 2003-12-18 | 2008-04-15 | Ethicon, Inc. | High strength suture with absorbable core and suture anchor combination |
US8974823B2 (en) | 2003-12-31 | 2015-03-10 | Bend Research, Inc. | Solid compositions of low-solubility drugs and poloxamers |
US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
AU2005213484A1 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | RNAi therapeutics for treatment of eye neovascularization diseases |
WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
NZ550964A (en) | 2004-04-28 | 2011-05-27 | Angiodevice Internat Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
CN100551448C (zh) | 2004-07-27 | 2009-10-21 | 帝斯曼知识产权资产管理有限公司 | 基于uhmwpe细丝的细长的手术用修补产品 |
WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
WO2006109177A1 (en) | 2005-04-13 | 2006-10-19 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
JP2009510182A (ja) | 2005-07-28 | 2009-03-12 | (オーエスアイ)アイテツク・インコーポレーテツド | シクリトールリンカーポリマー抱合体 |
JP2009506068A (ja) * | 2005-08-25 | 2009-02-12 | エモリー・ユニバーシティ | Hif阻害剤 |
US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US20070093461A1 (en) | 2005-10-26 | 2007-04-26 | Bausch & Lomb Incorporated | Effect of Loteprednol etabonate on vascular dysfunction |
EP1962803A1 (en) | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US8663674B2 (en) | 2006-01-13 | 2014-03-04 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
WO2007089864A2 (en) | 2006-01-30 | 2007-08-09 | Angiotech Pharmaceuticals, Inc. | Sutures and fibrosing agents |
EP1818348A1 (en) | 2006-02-10 | 2007-08-15 | Mnemoscience GmbH | Polymer material for useful medical devices |
US20070231360A1 (en) | 2006-03-28 | 2007-10-04 | Minu, L.L.C. | Neural conduit agent dissemination |
US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
US20070249536A1 (en) | 2006-04-25 | 2007-10-25 | Ma Peter X | Three-component polyanhydride copolymers and a method of forming the same |
EP2018361A4 (en) | 2006-05-15 | 2011-12-14 | Tyco Healthcare | HALOGENATED CYCLIC LACTONES AND POLYMERS COMPRISING SUCH LACTONES |
KR100787131B1 (ko) * | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 |
WO2008006535A2 (en) | 2006-07-10 | 2008-01-17 | Medigene Ag | Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases |
AU2007277035A1 (en) | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating or preventing ophthalmic light toxicity |
WO2008030557A2 (en) | 2006-09-08 | 2008-03-13 | Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
US8821943B2 (en) | 2006-09-12 | 2014-09-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
US8394488B2 (en) | 2006-10-06 | 2013-03-12 | Cordis Corporation | Bioabsorbable device having composite structure for accelerating degradation |
KR20090082447A (ko) | 2006-11-09 | 2009-07-30 | 알콘 리서치, 리미티드 | 약물 전달용 수불용성 폴리머 매트릭스 |
US8309222B2 (en) | 2007-04-25 | 2012-11-13 | Covidien Lp | Coated filaments |
US20090011040A1 (en) | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
US20080287341A1 (en) | 2007-05-18 | 2008-11-20 | Danyang Chen | Treatment of vascular abnormalities using nanoparticles |
CA2690244C (en) * | 2007-06-26 | 2016-08-09 | Ofra Benny-Ratsaby | Metap-2 inhibitor polymersomes for therapeutic administration |
US8217134B2 (en) | 2007-08-30 | 2012-07-10 | Bezwada Biomedical, Llc | Controlled release of biologically active compounds |
US20120028910A1 (en) | 2007-10-08 | 2012-02-02 | Jean-Philippe Combal | Storage-stable aqueous ophthalmic formulations |
WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
US20090226531A1 (en) | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
TW201019963A (en) | 2008-09-10 | 2010-06-01 | Abbott Lab | Polyethylene glycol lipid conjugates and uses thereof |
EP2355853B1 (en) | 2008-10-10 | 2016-12-07 | Polyactiva Pty Ltd | Biodegradable polymer - bioactive moiety conjugates |
US20100094340A1 (en) | 2008-10-15 | 2010-04-15 | Tyco Healthcare Group Lp | Coating compositions |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US20100152831A1 (en) | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Implantable Medical Devices Having Multiblock Copolymers |
WO2010091187A2 (en) | 2009-02-04 | 2010-08-12 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
US8062653B2 (en) | 2009-02-18 | 2011-11-22 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
EP2403335B1 (en) | 2009-03-03 | 2014-08-20 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
WO2010114770A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
AU2010280688A1 (en) | 2009-08-05 | 2012-02-23 | Allergan, Inc. | Controlled release formulations of lipocalin muteins |
US20130226234A1 (en) | 2009-11-16 | 2013-08-29 | Angiotech Pharmaceuticals, Inc. | Braided self-retaining sutures and methods |
EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
GB0922624D0 (en) | 2009-12-24 | 2010-02-10 | Croda Int Plc | Inverse emulsions |
NL2004047C2 (en) | 2010-01-04 | 2011-07-05 | D O R C Dutch Ophthalmic Res Ct International B V | An ophthalmic surgical device and a method of performing ophthalmic surgery. |
WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
US9198568B2 (en) | 2010-03-04 | 2015-12-01 | The General Hospital Corporation | Methods and systems of matching voice deficits with a tunable mucosal implant to restore and enhance individualized human sound and voice production |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
CA2816977C (en) | 2010-11-05 | 2019-10-29 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
CA2830961C (en) | 2011-03-23 | 2018-12-04 | Ethicon, Llc | Self-retaining variable loop sutures |
WO2012131362A2 (en) | 2011-03-29 | 2012-10-04 | Sun Chemical B.V. | A two-coat barrier system comprising polyurethane |
EP2790733B1 (en) | 2011-12-14 | 2019-10-30 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
US20130217657A1 (en) | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
EP2804632B1 (en) | 2012-01-19 | 2019-09-18 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
CN104394891B (zh) | 2012-03-16 | 2019-04-16 | 约翰霍普金斯大学 | 用于递送活性剂的非线性多嵌段共聚物-药物结合物 |
CA2867381C (en) * | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2871745C (en) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
CA2871748C (en) | 2012-05-03 | 2021-07-06 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US20140178475A1 (en) | 2012-09-17 | 2014-06-26 | Bind Therapeutics, Inc. | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same |
US20150265541A1 (en) | 2012-09-20 | 2015-09-24 | Akina, Inc. | Biodegradable Microcapsules Containing Filling Material |
WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
KR20150139899A (ko) | 2013-04-01 | 2015-12-14 | 알러간, 인코포레이티드 | 지속적인 안구내 방출을 위한 마이크로스피어 약물 전달 시스템 |
-
2013
- 2013-03-12 CA CA2867381A patent/CA2867381C/en active Active
- 2013-03-12 EP EP13711263.7A patent/EP2825206A1/en not_active Ceased
- 2013-03-12 US US13/797,506 patent/US8962577B2/en active Active
- 2013-03-12 WO PCT/US2013/030533 patent/WO2013138343A1/en active Application Filing
- 2013-03-12 AU AU2013232297A patent/AU2013232297B2/en not_active Ceased
- 2013-03-12 EA EA201491710A patent/EA032552B1/ru unknown
- 2013-03-12 CN CN201380025514.6A patent/CN104363924B/zh not_active Expired - Fee Related
- 2013-03-12 JP JP2015500518A patent/JP5883539B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-19 US US14/599,853 patent/US9950072B2/en active Active
- 2015-07-21 HK HK15106964.2A patent/HK1206270A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2825206A1 (en) | 2015-01-21 |
CN104363924B (zh) | 2018-04-17 |
JP5883539B2 (ja) | 2016-03-15 |
EA032552B1 (ru) | 2019-06-28 |
US8962577B2 (en) | 2015-02-24 |
WO2013138343A1 (en) | 2013-09-19 |
CN104363924A (zh) | 2015-02-18 |
AU2013232297B2 (en) | 2016-01-14 |
JP2015511987A (ja) | 2015-04-23 |
AU2013232297A1 (en) | 2014-10-23 |
HK1206270A1 (zh) | 2016-01-08 |
US20150141359A1 (en) | 2015-05-21 |
CA2867381A1 (en) | 2013-09-19 |
US20130274217A1 (en) | 2013-10-17 |
EA201491710A1 (ru) | 2015-04-30 |
US9950072B2 (en) | 2018-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11660349B2 (en) | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents | |
CA2867381C (en) | Controlled release formulations for the delivery of hif-1 inhibitors | |
EP3233056B1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
US20180008718A1 (en) | Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure | |
KR20140103099A (ko) | 안구 병태의 예방 및 치료 | |
JP2017524712A (ja) | 角膜同種移植片拒絶および新血管形成を予防するためのグルココルチコイドを負荷したナノ粒子 | |
KR102642432B1 (ko) | 약물-중합체 접합체 | |
US20190022016A1 (en) | Compositions for sustained release of anti-glaucoma agents to control intraocular pressure | |
US20190275001A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140912 |